Extractables and Leachables Testing: When USP Risk Gaps Delay Approval

For enterprise decision-makers, extractables and leachables testing has moved far beyond a narrow lab exercise. It now sits directly on the approval path, especially when USP language does not fully answer product-specific risk questions.

That gap creates a familiar problem. A submission looks complete on paper, yet reviewers still ask how polymers, process fluids, sterilization, storage, and patient exposure were linked into one defensible story.

In life science supply chains, that story matters across single-use plastics, cell culture reagents, chromatography media, IVD components, and sterile packaging. If the risk logic is weak, approval slows, launch slips, and commercial confidence drops.

The good news is that most delays in extractables and leachables testing are preventable. The key is to close USP risk gaps before they become reviewer objections.

Where USP Risk Gaps Usually Appear

USP chapters are useful, but they are not a shortcut to product understanding. They provide a framework, not a complete justification for every material, process condition, or route of exposure.

The biggest delays in extractables and leachables testing usually appear when teams assume general compliance language will satisfy a very specific regulatory question.

• Start with patient and product exposure, not test tradition. A valid study plan should connect contact time, temperature, dosage form, and material chemistry before protocols are locked.
• Map every polymer and additive source early. Many delays come from undocumented colorants, slip agents, adhesives, inks, gaskets, and multilayer packaging components outside the main bill of materials.
• Separate “USP aligned” from “submission ready.” A material may meet a compendial reference yet still lack sufficient justification for process-specific leachables risk and toxicological relevance.
• Check whether sterilization changes chemistry. Gamma, EO, steam, and irradiation can create new degradation products that basic extractables studies may not predict well enough.
• Review analytical sensitivity against real reporting needs. If thresholds are too high, critical unknowns remain hidden until regulators request repeat work under tighter limits.

Why this hits LSRS-covered sectors hard

LSRS tracks categories where purity, consistency, and contact risk are commercially decisive. A pipette tip, a bioprocess bag film, a resin housing, or a sterile barrier layer may look routine, but each can become an E&L bottleneck.

That is especially true in global innovative drugs and gene therapy scale-up, where process intensification, long hold times, and cross-border submissions raise the standard for defensible extractables and leachables testing.

The practical checks worth doing before studies begin

A strong plan is less about running more tests and more about asking the right questions in the right order. That is where many teams save months.

• Define the true worst case with evidence. Use process temperature, solvent strength, exposure duration, and surface-area-to-volume ratio from actual operations, not generic assumptions.
• Align suppliers around one data package. Material vendors, converters, sterilizers, and fill-finish partners should support the same composition, change-control, and analytical narrative.
• Build toxicological review into the timeline early. Unknown peaks become costly when analytical work finishes first and safety interpretation starts too late.
• Use orthogonal methods for ambiguous compounds. GC-MS alone rarely answers everything; LC-MS, ICP-MS, and targeted confirmation often prevent back-and-forth with reviewers.
• Document why excluded components are low risk. A clear scientific rationale for non-contact or negligible-contact parts reduces unnecessary test expansion later.

A common submission scenario

Consider a single-use fluid path used in biologics manufacturing. The base film was tested, but tubing welds, clamps, filter housings, and post-sterilization aging were treated as minor details.

Reviewers then ask a simple question: how do the reported extractables represent the assembled system actually used in production? If that answer is weak, approval timing slips fast.

What often gets missed in extractables and leachables testing

Most programs do not fail because teams ignore E&L entirely. They fail because seemingly small omissions break the logic chain between material characterization and real-world use.

• Aging effects are underestimated. Shelf life, transport vibration, light exposure, and cold-chain stress can shift leachable profiles long after initial extractables studies are closed.
• Process intermediates are ignored. Buffer concentrates, lipid systems, alcohols, surfactants, and cryoprotectants may pull different compounds than purified water screening suggests.
• Change control is treated as procurement, not quality risk. A resin support, stopper formula, or packaging laminate change can invalidate earlier justification if not reassessed promptly.
• Unknown identification stops too early. “Below concern” is not always persuasive when repeated unknowns appear across batches or under clinically relevant conditions.
• Regional filing expectations are not compared. What passes one market may trigger extra justification elsewhere, especially for combination products and high-risk sterile applications.

Another high-risk example

In sterile packaging, barrier performance usually gets most of the attention. Yet extractables and leachables testing can become the hidden issue when adhesives, coatings, or printing layers are not adequately assessed.

That matters for long ocean transport and terminal sterilization. A package can remain intact and still raise chemical compatibility questions that delay device or kit approval.

How to tighten the approval story

The most effective response is to build a cleaner decision path. Reviewers do not just want data. They want to see that the data reflects realistic use, controlled materials, and clear risk ownership.

• Write the risk assessment as if it will be challenged. Every assumption in extractables and leachables testing should trace back to material facts, process use, or toxicological logic.
• Treat assembled systems as assembled systems. For SUS, IVD, and packaged sterile products, component-level data alone often fails to represent real contact conditions.
• Link quality and commercial planning. If approval depends on one supplier’s incomplete chemistry disclosure, the business risk is larger than the analytical gap.
• Use expert review before filing, not after objections arrive. An external challenge session often reveals weak justifications faster than internal consensus does.

Why LSRS intelligence is relevant here

LSRS follows the categories where E&L risk intersects directly with purity, yield, sterility, and cost. That includes lab single-use plastics, high-end cell culture media, chromatography purification media, IVD kits, and medical-grade sterile packaging.

This matters because extractables and leachables testing does not live in isolation. It affects process robustness, export readiness, supplier qualification, and even COGS when late changes force revalidation.

The next move when timing is tight

If approval risk is rising, do not start by ordering more tests blindly. First, check whether the current package answers five core questions: what contacts what, under which conditions, for how long, with what chemistry, and with what safety margin.

When those answers are clear, extractables and leachables testing becomes a decision tool instead of a delay source. When they are vague, even good data can fail to move a submission forward.

A practical next step is to review material disclosure, worst-case assumptions, analytical sensitivity, toxicology timing, and change-control readiness in one cross-functional pass. That single exercise often reveals the exact gap slowing approval confidence.

In a market built on ultra-clean materials and reliable biological performance, stronger extractables and leachables testing is not just compliance protection. It is a faster route to credible filings, steadier supply, and fewer surprises after scale-up.